UBS upgraded Option Care Health (OPCH) to Buy from Neutral with a price target of $40, up from $38. The company’s Q1 results evidenced strong earnings momentum, despite a $5M impact from Stelara, which was more muted than anticipated given inventory management actions taken by Option, the analyst tells investors in a research note. The firm sees an attractive entry point at current share levels and continues to believe the company will see benefits from a secular shift in site of care from institutional to the home.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Option Care Health: Strong Growth Prospects and Strategic Market Position Justify Buy Rating
- Option Care Health Reports Strong Q1 2025 Results
- Option Care Health’s Earnings Call Highlights Strong Growth
- Option Care Health: Strong Financial Performance and Raised Guidance Justify Buy Rating